How to prevent glucocorticoid-induced osteoporosis

Cleveland Clinic Journal of Medicine

Volumn 77, Issue 8, 2010, Pages 529-536

  Dore, Robin K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CALCIUM; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; VITAMIN D;

BONE; BONE DENSITY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FRACTURE; HORMONE SUBSTITUTION; HUMAN; OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; CHEMICALLY INDUCED; DRUG EFFECTS; FRACTURES, BONE;

BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DIPHOSPHONATES; FRACTURES, BONE; GLUCOCORTICOIDS; GUIDELINE ADHERENCE; HORMONE REPLACEMENT THERAPY; HUMANS; IMMUNOLOGIC FACTORS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; VITAMIN D;

EID: 77956554535     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77a.10003     Document Type: Review

References (35)

1. Bouvard B, Legrand E, Audran M, Chappard D. Glucocorticoid-induced osteoporosis: a review. Clin Rev Bone Miner Metab 2010; 8:15-26.
2. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 2008; 58:1674-1686.
3. Manolagas SC. Corticosteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res 2000; 15:1001-1005.
4. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999; 14:1061-1066.
5. Canalis E, Bilezikian JP, Angeli A, Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 2004; 34:593-598.
6. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005; 329:177-181.
7. Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 2009; 5:20-27.
8. Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998; 27:465-483.
9. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoidinduced and postmenopausal osteoporosis. J Bone Miner Res 2001; 16:97-103.
10. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93:105-111.
11. Curtiss PH Jr, Clark WS, Herndon CH. Vertebral fractures resulting from prolonged cortisone and corticotropin therapy. J Am Med Assoc 1954; 156:467-469.
12. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13:777-787.
13. van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48:3224-3229.
14. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000; 355:1399-1403.
15. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16:581-588.
16. Weldon D. The effects of corticosteroids on bone growth and bone density. Ann Allergy Asthma Immunol 2009; 103:3-11.
17. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44:1496-1503.
18. Compston J, Barlow D, Brown P, et al. Glucocorticoidinduced osteoporosis. Guidelines for prevention and treatment. London: Royal College of Physicians; 2002. http://www.rcplondon.ac.uk/pubs/books/glucocorticoid/Glucocorticoid.pdf. Accessed 5/20/2010.
19. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroidinduced osteoporosis. Cochrane Database Syst Rev 2000; (2):CD000952.
20. Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoidinduced bone loss: a 12-month randomized, placebocontrolled clinical trial. J Rheumatol 2009; 36:1705-1714.
21. Bianchi ML. Glucorticoids and bone: some general remarks and some special observations in pediatric patients. Calcif Tissue Int 2002; 70:384-390.
22. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288:321-333.
23. Compston JE. The risks and benefits of HRT. J Musculoskelet Neuronal Interact 2004; 4:187-190.
24. Reid IR, Ibbertson HK, France JT, Pybus J. Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. Br Med J (Clin Res Ed) 1985; 291:574.
25. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156:1173-1177.
26. Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003; 88:3167-3176.
27. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006; 91:1995-2010.
28. Cranney A, Welch V, Adachi J, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; (2):CD0019830.
29. Reid DM, Devogelaer JP, Saag K, et al; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373:1253-1263.
30. Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008; 23:6-16.
31. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809-1822.
32. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028-2039.
33. Dore RK, Cohen SB, Lane NE, et al; Denosumab RA Study Group. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010; 69:872-875.
34. Blalock SJ, Norton LL, Patel RA, Dooley MA. Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2005; 53:732-739.
35. Curtis JR, Westfall AO, Allison JJ, el al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoidtreated patients. Arthritis Rheum 2005; 52:2485-2494.